Reducing the global breast cancer burden: The importance of patterns of care research

Clinical Breast Cancer

Volumn 6, Issue 5, 2005, Pages 412-420

  Albain, Kathy S ^a   de la Garza Salazar, Jaime ^b   Pienkowski, Tadeusz ^c   Aapro, Matti ^d   Bergh, Jonas ^e   Caleffi, Maira ^f   Coleman, Robert ^g   Eiermann, Wolfgang ^h   Içli, Fikri ⁱ   Pegram, Mark ^j   Piccart, Martine ^k   Snyder, Raymond ^l   Toi, Masakazu ^m   Hortobagyi, Gabriel N ⁿ  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d CLINIQUE DE GENOLIER   (Switzerland)

^e KAROLINSKA INSTITUTE   (Sweden)

^f HOSPITAL MOINHOS DE VENTO   (Brazil)

^g WESTON PARK HOSPITAL   (United Kingdom)

^h Redcross Women's Hospital   (Germany)

ⁱ ANKARA UNIVERSITY   (Turkey)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k JULES BORDET INSTITUTE   (Belgium)

^l ST VINCENT S HOSPITAL   (Australia)

^m TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Global registry; Outcomes; Treatment guidelines

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ACCURACY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; FOLLOW UP; GEOGRAPHY; HEALTH CARE AVAILABILITY; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; INFORMATION PROCESSING; MEDICAL DECISION MAKING; META ANALYSIS; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 30544434321     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.045     Document Type: Review

References (81)

1. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19:3817-3827.
2. National Institutes of Health. Adjuvant therapy for breast cancer. NIH Consensus Statement 2000; 17:1-23.
3. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2000; (3):CD000485.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001; (1):CD000486.
5. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2002; (1):CD000487.
6. Early Breast Cancer Trialists' Collaborative Group. Radiotherapy for early breast cancer. Cochrane Database Syst Rev 2002; (2):CD003647.
7. Kosecoff J, Kanouse DE, Brook RH. Changing practice patterns in the management of primary breast cancer: Consensus Development Program. Health Serv Res 1990; 25:809-823.
8. Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 1999; 86:628-637.
9. Harlan LC, Abrams J, Warren JL, et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 2002; 20:1809-1817.
10. Palazzi M, De Tomasi D, D'Affronto C, et al. Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients. Tumori 2002; 88:503-506.
11. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997; 157:408-416.
12. Bickell NA, Aufses AH Jr, Chassin MR. The quality of early-stage breast cancer care. Ann Surg 2000; 232:220-224.
13. Link BK, Budd GT, Scott S, et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001; 92:1354-1367.
14. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001; 19:1455-1461.
15. Roila F, Ballatori E, Patoia L, et al. Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol 2003; 14:843-848.
16. Bloom BS, de Pouvourville N, Chhatre S, et al. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer 2004; 90:26-30.
17. Hebert-Croteau N, Brisson J, Latreille J, et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004; 22:3685-3693.
18. Silliman RA. Crossing the quality chasm in breast cancer care. J Clin Oncol 2004; 22:3654-3656.
19. Guadagnoli E, Shapiro CL, Weeks JC, et al. The quality of care for treatment of early stage breast carcinoma: is it consistent with national guidelines? Cancer 1998; 83:302-309.
20. Hebert-Croteau N, Brisson J, Latreille J, et al. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 1999; 85:1104-1113.
21. Institute of Medicine. Medicare: A Strategy for Quality Assurance, Volume II: Sources and Methods. Washington, DC: National Academy Press; 1990.
22. Hewitt M, Simone JV, eds. Ensuring Quality Cancer Care. Washington, DC: National Academy Press; 1999.
23. Hebert-Croteau N, Brisson J, Latreille J, et al. Variations in the treatment of early-stage breast cancer in Quebec between 1988 and 1994. CMAJ 1999; 161:951-955.
24. Albain KS, Green SR, Lichter AS, et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol 1996; 14:3009-3017.
25. Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med 1992; 326:1097-1101.
26. White J, Morrow M, Moughan J, et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003; 97:893-904.
27. Olivotto A, Coldman AJ, Hislop TG, et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 1997; 15:216-222.
28. Hebert-Croteau N, Brisson J, Latreille J, et al. Time trends in systemic adjuvant treatment for node-negative breast cancer. J Clin Oncol 1999; 17:1458-1464.
29. Kingsmore D, Hole D, Gillis C. Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer 2004; 90:1920-1925.
30. Sainsbury R, Haward B, Rider L, et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995; 345:1265-1270.
31. Schleifer SJ, Bhardwaj S, Lebovits A, et al. Predictors of physician non-adherence to chemotherapy regimens. Cancer 1991; 67:945-951.
32. Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996; 88:716-726.
33. Hillner BE, Penberthy L, Desch CE, et al. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat 1996; 40:75-86.
34. De Michele A, Putt M, Zhang Y, et al. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 2003; 97:2150-2159.
35. Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 2003; 138:90-97.
36. Sant M. Differences in stage and therapy for breast cancer across Europe. EUROCARE Working Group. Int J Cancer 2001; 93:894-901.
37. Malin JL, Schuster MA, Kahn KA, et al. Quality of breast cancer care: what do we know? J Clin Oncol 2002; 20:4381-4393.
38. Richardson LC. Treatment of breast cancer in medically underserved women: a review. Breast J 2004; 10:2-5.
39. Liberati A, Patterson WB, Biener L, et al. Determinants of physicians' preferences for alternative treatments in women with early breast cancer. Tumori 1987; 73:601-609.
40. McFall SL, Warnecke RB, Kaluzny AD, et al. Physician and practice characteristics associated with judgments about breast cancer treatment. Med Care 1994; 32:106-117.
41. Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care 2003; 41:442-446.
42. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997; 277:1485-1492.
43. Baum M, Ravdin PM. Decision-making in early breast cancer: guidelines and decision tools. Eur J Cancer 2002; 38:745-749.
44. Sant M, Caposcaccia. R, Verdecchia A, et al. Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The EUROCARE Working Group. Int J Cancer 1998; 77:679-683.
45. Quinn MJ, Martinez-Garcia C, Berrino F, et al. Variations in survival from breast cancer in Europe by age and country, 1978-1989. Eur J Cancer 1998; 34:2204-2211.
46. Craft PS, Primrose JG, Lindner JA, et al. Surgical management of breast cancer in Australian women in 1993: analysis of Medicare statistics. Med J Aust 1997; 166:626-629.
47. Nattinger AB, Gottlieb MS, Veum J, et al. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992; 326:1102-1107.
48. Morrow M, White J, Moughan J, et al. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 2001; 19:2254-2262.
49. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2:133-140.
50. Mariotto A, Feuer EJ, Harlan LC, et al. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002; 94:1626-1634.
51. Hill DJ, White VM, Giles GG, et al. Changes in the investigation and management of primary operable breast cancer in Victoria. Med J Aust 1994; 161:110-111.
52. Sant M, Allemiani C, Capocaccia R, et al., and the EUROCARE Working Group. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003; 106:416-422.
53. Botha JL, Bray F, Sankila R, et al. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003; 39:1718-1729.
54. Nyström L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359:909-919.
55. Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003; 361:1405-1410.
56. Ayanian JZ, Kohler BA, Abe T, et al. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 1993; 329:326-331.
57. Purushotham AD, Pain SJ, Miles D, et al. Variations in treatment and survival in breast cancer. Lancet Oncol 2001; 2:719-725.
58. Goldhirsch A, Colleoni M, Domenighetti G, et al. Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol 2003; 14:1212-1214.
59. Vervoort MM, Draisma G, Fracheboud J, et al. Trends in the usage of adjuvant systemic therapy for breast cancer in The Netherlands and its effect on mortality. Br J Cancer 2004; 91:242-247.
60. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press; 2004. Available at: http://www-dep.iarc.fr/. Accessed December 15, 2004.
61. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004; 54:78-93.
62. Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003; 53:342-355.
63. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 1994; 272:947-954.
64. McCarthy EP, Burns RB, Coughlin SS, et al. Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 1998; 128:729-736.
65. Lannin DR, Mathews HF, Mitchell J, et al. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA 1998; 279:1801-1807,
66. Dignam JJ, Redmond CK, Fisher B, et al. Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer 1997; 80:80-90.
67. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 2002; 94:490-496.
68. Joslyn S.A. Racial differences in treatment and survival from early-stage breast carcinoma. Cancer 2002; 95:1759-1766.
69. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002; 94:334-357.
70. Bach PB, Schrag D, Brawley OW, et al, Survival of blacks and whites after a cancer diagnosis. JAMA 2002; 287:2106-2113.
71. Heimann R, Ferguson D, Powers C, et al. Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation. J Clin Oncol 1997; 15:2329-2337.
72. Albain KS, Unger JM, Hutchins LF, et al. Outcome of African Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. Breast Cancer Res Treat 2003; 82(suppl 1):S12 (Abstract #21).
73. Woodward WA, Huang EH, McNesse MD, et al. African-American patients with breast cancer have worse overall survival than Caucasian and Hispanic patients after mastectomy and doxorubicin-based chemotherapy: data from two independent data sets. Breast Cancer Res Treat 2003; 24(suppl 1):S145 (Abstract #613).
74. Hiotis KL, Ye W, Sposto R, et al. The demographics of breast cancer survival; is it sociology or biology? Breast Cancer Res Treat 2003; 82(suppl 1):S149 (Abstract #622).
75. Swan J, Wingo P, Clive R, et al. Cancer surveillance in the US: can we have a national system? Cancer 1998; 83:1282-1291.
76. Pearson ML, Ganz PA, McGuigan K, et al. The case identification challenge in measuring quality of cancer care. J Clin Oncol 2002; 20:4353-4360.
77. Jonkman JN, Normand SL, Wolf R, et al. Identifying a cohort of patients with early-stage breast cancer: a comparison of hospital discharge and primary data. Med Care 2001; 39:1105-1117.
78. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002; 40(suppl 8):IV55-IV61.
79. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76:2343-2350.
80. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 1997; 50:939-945.
81. Kahn KL, Malin JL, Adams J, et al. Developing a reliable, valid, and feasible plan for quality-of-care measurement for cancer: how should we measure? Med Care 2002; 40(suppl 6):III73-III85.